Remus Pharmaceuticals (NSE:REMUS) Total Stockholders Equity: ₹3,510 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
56 GF Score
Price ₹878.75
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Total Stockholders Equity?

Remus Pharmaceuticals NSE:REMUS -1.27% 56 Total Stockholders Equity is ₹3,510 Mil as of Mar. 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 56/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Remus Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2026 was ₹3,510 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Remus Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 was ₹371.85. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Remus Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.08.

Remus Pharmaceuticals  (NSE:REMUS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Remus Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3509.9-0)/9.439
=371.85

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Remus Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(183.8 + 86.9) / 3509.9
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Total Stockholders Equity Related Terms

Remus Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Total Stockholders Equity Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Stockholders Equity
Get a 7-Day Free Trial 64.32 190.80 1,576.90 2,558.60 3,509.90

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,576.90 1,004.88 2,558.60 3,069.90 3,509.90
NSE:REMUS
56GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of ₹3,510 Mil mean?
Remus Pharmaceuticals (NSE:REMUS) has a Total Stockholders Equity of ₹3,510 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Total Stockholders Equity too high?
Remus Pharmaceuticals' current Total Stockholders Equity is ₹3,510 Mil. Overall, Remus Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Total Stockholders Equity compare to MCK and COR?
Remus Pharmaceuticals' Total Stockholders Equity of ₹3,510 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Distribution company?
A good Total Stockholders Equity depends on the Medical Distribution industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Total Stockholders Equity is ₹3,510 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹878.75 — trading 57.6% below its estimated fair value. The current Total Stockholders Equity is ₹3,510 Mil. Remus Pharmaceuticals' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Total Stockholders Equity is ₹3,510 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹878.75 is trading 57.6% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Total Stockholders Equity: ₹3,510 Mil
  • GF Value™: ₹2,071.36 vs. price of ₹878.75 (57.6% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
56GF Score

Get the complete analysis for NSE:REMUS

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹878.75
Price
₹2,071.36
GF Value